	expert	9.001475455264993
	generic product	6.755528904691135
	principal challenge	6.754662911649391
	post verdict motion	4.508382398855386
¡°	trandolapril ACE inhibitor	3.319208662529637
¡°	enzyme ACE inhibitor trandolapril	2.2979707313107585
¡°	Tarka (r) combination	2.173832146313915
¡°	Tarka (r) product	2.1733304992046416
	calcium antagonist drug	1.9055040343878131
	effective ACE inhibitor calcium channel blocker	1.8802209514898365
	one known ACE inhibitor	1.7144226673011331
	previously know ACE inhibitor	1.7092709899638483
	ACE enzyme	1.6892396450316365
	verapamil hydrochloride	1.5368313073649191
¡°	double ring trandolapril	1.4107493852723507
	quinapril	1.2416309092638282
	single ring ACE inhibitor	1.2122629750606846
	Germany	1.0922611169530574
	evidence spoliation	1.0762606342779846
	standing	0.8550932845078869
	angiotensin convert enzyme inhibitor	0.8106000789829043
	single ring double ring ACE inhibitor	0.7886117582137185
	Launch	0.7181154194577481
	single ring inhibitor	0.6792121632538003
	two hypertension medication	0.5925725397878983
	double ring inhibitor	0.5782875979908088
	finality	0.5215730108759215
	destruction	0.47896639224872495
	prior art hypertension treatment	0.4344412027362545
	Potter	0.41422796092246056
	Captopril	0.41422796092246056
	improve kidney function	0.29012576884064295
	antihypertension drug	0.2585459498306133
	VALIDITY	0.20711398046123028
	improved kidney blood vessel function	0.1575704582902617
	France	0.1428175728281414
	Nephew	0.1428175728281414
	physician	0.1428175728281414
	pocket	0.14269655804544787
	distributor	0.13650872078548873
	enzyme activity	0.13002568603290796
	double ring product	0.1225389929524553
	Robert Bosch	0.11369643835217498
	Abbott United States company	0.1114119230473511
	unpredicted superior property	0.11140439797244174
	single ring structure	0.10959585410890785
	Abbott Laboratories Inc. United States company	0.10747976024328496
	Kinetic Concepts	0.1070257914256655
	double patenting	0.10636941140077313
	Sanofi Aventis Deutschland GmbH	0.1061998012893877
	Hatch Waxman Paragraph IV Certification	0.0908659808810402
	double ring compound	0.08903549982588166
	different perception	0.08700836521661472
	Aventis Pharma S.A.	0.08227487745569
	price erosion damage	0.08051991811877711
	single ring compound	0.07477652697372152
	order denomination	0.06903988762182227
	worker	0.06834117350216397
	multiple daily dose	0.06188250294120943
	lose profit	0.060676826843239176
	improved blood vessel structure	0.05925195968472951
	magic word	0.05472612936287712
	ANDA	0.049990086194111355
	daily dosing	0.04238224899981384
	class	0.034237405418074664
	hundred	0.03331895374264946
	unexpected advantageous property	0.031253533754475836
	previously unavailable extend improve efficacy	0.02924368633972264
	one drug	0.02876121520918294
	care	0.02805377343693225
	approve drug application	0.02537362731980695
	prejudicial jury instruction	0.024727272815692123
	generic counterpart	0.022209109594558588
	abbreviate drug application	0.021287498270127984
	formula	0.02062253280343451
	combination drug	0.019894745182347656
	combination therapy	0.01931487769543916
	Trial	0.01898056658722949
	item	0.01898056658722949
	permanent injunction	0.01834966639267113
	authority	0.018211043397822348
	civil action	0.018108745130162893
	jury verdict	0.017904432946366153
	post verdict damage	0.017412987915143858
	longer last effectiveness	0.015827040262023667
	short duration	0.014509680120293642
	longer last control	0.014251173129384152
	dosage requirement	0.013647510900726545
	New Jersey	0.013301091317884331
	final calculation	0.012386398580300157
	Newman	0.011721978561435586
	post verdict judgment	0.01151115696875057
	preliminary injunction	0.010450828216744737
	post judgment damage	0.010353653065167265
	risk	0.01031563928875629
	single dosage product	0.01030874419264986
	FDA	0.009685732289203336
	provision	0.009109383243775748
	renew motion	0.00797225976812307
	additional damage	0.007899683491760652
	prior art study	0.007595438890471934
	Food Drug Administration	0.006661124738695873
	something	0.006025678756867003
	Elec	0.005381952936566408
	request	0.005314991169779189
	pharmaceutical composition	0.004827401189240681
	implicit factual finding	0.00478894709044028
	different expectation	0.004560501105004088
	post trial motion	0.004470876071395349
	day	0.0043265184356002994
	statute	0.004314625275249137
	holder motion	0.00409972109580781
	New Drug Application	0.004062518877590348
	LLC	0.0039429806334768695
	collectively	0.003873225288981902
	two active ingredient	0.0037052170217890513
	potential combination	0.0036255570623201197
	previously know treatment	0.00345204080728598
	significant advantage	0.003423972011161644
	separate document requirement	0.0031487479510358
	Rule	0.002917016999398241
	incorrect law	0.002810493144398174
	appellate jurisdiction	0.002773355240859633
	defense	0.0026403955811190533
	content	0.0020031251179106523
	June	0.001961079295077867
	nonobviousness	0.0018751138523485753
	combination product	0.0011585112944040791
	owner	0.001143884496876935
	previously test combination	0.0010598257676746718
	none	0.0008457511027129544
	patentability	0.0008436425085157452
	every combination	0.0007978671984419998
	factual component	0.0007773200709036438
	every pende	0.000768895633788672
	district court discretion	0.0007338207837359943
	September	0.0007291790075807053
	prior art component	0.0005712167413347551
	district court issuance	0.0005646503635574395
	Federal Circuit jurisdiction	0.0005267389892269511
	amount	0.0004126260720939185
	substantial evidence	0.0003003666151298683
	objective evidence	0.00029636264763808215
	available information	0.0002542163051654133
	nothing	0.00024121831576606414
	important consideration	0.00020699197224153892
	validity	0.00019483813030667408
	final judgment rule	0.0001770715049685016
	suit	0.00016171908835776907
	obviousness type	0.00013707574306142441
	lack	0.00011304609597900416
	clear convincing evidence	0.00010888662655790872
	underlie fact	7.926230343789618e-05
	banc	7.733088620422308e-05
	background	6.890234357422132e-05
	competitor motion	4.410749751565267e-05
	favor	3.911598677689975e-05
	holding	3.5413349321449955e-05
	ordinary skill	2.3577120643698253e-05
	legal conclusion	1.641252689260615e-05
	purpose	8.726815726656128e-06
	analysis	6.859002018445614e-06
	view	5.8516332941291555e-06
	regard	5.8119468498064e-06
	Idaho	9.963976330619925e-07
	infringement action	2.0962934260000354e-07
	support fact	1.2349317050622952e-07
	also state	8.686088852764942e-08
	prior art reference	4.174886305363889e-08
	district court judgment	8.772694813417922e-09
	use	2.476175439309848e-09
	invention	2.15901788768946e-09
	District	0.0
	Appeals	0.0
	United States Court	0.0
